Key Points
- CFO Ivan Hyep sold 1,882 shares of Bicara Therapeutics (BCAX) on Jan. 22 at an average price of $18.15 for $34,158, trimming his stake to 145,355 shares; he also sold 17,795 shares on Nov. 24 and 605 shares on Nov. 21 in earlier transactions.
- Bicara is currently unprofitable (last quarter EPS -$0.67; analysts forecast -2.59 EPS for the year) but has a consensus rating of "Moderate Buy" with an average target price of $28, while trading within a 52‑week range of $7.80–$19.71 and a market cap around $899M.
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 1,882 shares of the stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $18.15, for a total value of $34,158.30. Following the completion of the transaction, the chief financial officer owned 145,355 shares of the company's stock, valued at $2,638,193.25. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Ivan Hyep also recently made the following trade(s):
- On Monday, November 24th, Ivan Hyep sold 17,795 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.55, for a total value of $330,097.25.
- On Friday, November 21st, Ivan Hyep sold 605 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.15, for a total transaction of $10,980.75.
Bicara Therapeutics Stock Performance
NASDAQ:BCAX opened at $16.42 on Tuesday. Bicara Therapeutics Inc. has a fifty-two week low of $7.80 and a fifty-two week high of $19.71. The company has a 50 day moving average price of $17.47 and a 200 day moving average price of $14.77. The stock has a market capitalization of $899.49 million, a P/E ratio of -7.33 and a beta of -0.79.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.12). Research analysts forecast that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Bicara Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Bicara Therapeutics during the 4th quarter worth approximately $45,000. Legal & General Group Plc grew its holdings in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock valued at $29,000 after purchasing an additional 1,233 shares during the period. Ameritas Investment Partners Inc. increased its holdings in shares of Bicara Therapeutics by 73.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company's stock worth $32,000 after buying an additional 1,474 shares during the last quarter. Larson Financial Group LLC increased its stake in Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock worth $62,000 after acquiring an additional 3,595 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock worth $44,000 after purchasing an additional 3,866 shares in the last quarter.
Analysts Set New Price Targets
A number of brokerages have recently commented on BCAX. UBS Group reissued a "buy" rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Wells Fargo & Company upped their price objective on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the company an "equal weight" rating in a research note on Tuesday, November 11th. Weiss Ratings restated a "sell (d-)" rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. Mizuho raised Bicara Therapeutics to a "hold" rating in a report on Thursday, December 18th. Finally, Wedbush restated an "outperform" rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday, January 13th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $28.00.
Check Out Our Latest Research Report on Bicara Therapeutics
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
